Growing Burden of End-Stage Diseases, Ever Increasing Waiting List for Organ Transplants & Worsening Organ Shortages Drive the Market for Artificial Organs
The
global market for Artificial Organs is projected to reach US$26.04 billion by 2024, driven by rising incidence of diseases, increasing
number of people on waiting list for donor organs, and impending launches such
as wearable artificial kidneys and initiatives such as The Kidney project.
The artificial organs market globally is expected to post a healthy
growth over the next decade due to the rising incidence of cardiovascular
diseases, acute kidney failures and renal disorders, respiratory conditions,
diabetes, and cirrhosis. Over the last several years, the healthcare sector has
been witnessing a strong demand for artificial organs, owing to widening gap
between the demand and availability of donor organs for organ transplantation
surgeries. In addition, there is always a risk
of rejection of the transplanted organ by the immune system of the recipient.
Artificial organs are developed using biomaterials, which are non-living or
living substances that are introduced in the human body as artificial organ for
replacing an original organ or its functions. Continuously expanding base of
geriatric population, increasing incidence of organ failure, man-made hazards
and higher number of accidents are responsible for driving the demand for
artificial organs. The market growth is also supported by continuous
improvements in medical technology and increasing investments in the
healthcare sector.
In the Artificial kidneys space, The Kidney Project gained attention
with its groundbreaking research on the development of an artificial kidney, in
February 2018. Upon receiving approval for human trials, and appropriate
funding thereafter, commercialization of the device in the near future is
expected to drive the artificial kidneys market. Developments in the ‘Wearable Artificial
Kidneys’ market is also a major driver.
Besides artificial kidney, advancements in other artificial organ
spaces, such as artificial liver, pancreas and artificial lungs, are likely to
drive the market growth. Researchers
from the Mayo Clinic undertook preclinical development of a bioartificial
liver, termed the Mayo
Spheroid Reservoir Bioartificial Liver (SRBAL). SRBAL showed higher levels
of ammonia clearance than previously developed bioartificial liver, and is
deemed to have high potential as bridge-to-transplantation device and also for
long term support of liver failure patients so as to avoid transplantation.
As stated by the new market research report on Artificial
Organs, the United States represents the single
largest market worldwide, driven by aging baby boomer population, rising
incidence of disease, and advancements undertaken in the various artificial
organs space. Developing economies are emerging as fast growing markets led by
improving healthcare infrastructure, rising healthcare awareness, and increasing
disposable income. One of the notable developments that are likely to assist
manufacturers is advent of the 3D bioprinting technology. An estimated 90% of
organizations believe in the powers of 3D printing and are increasingly
investing in 3D print solutions.
Key players in the market include Abbott., Abiomed Inc.,
Asahi Kasei Medical Co., Ltd., Baxter International Inc., F.Hoffmann-La Roche
Ltd., Fresenius Medical Care AG & Co. KGaA, HeartWare International Inc., Jarvik Heart Inc., Medtronic Inc., Nikkiso Co. Ltd., Nipro Corp., SynCardia
Systems LLC, Toray Medical Co., Ltd., and Xenios AG, among others.
The research report
titled “Artificial Organs - Market Analysis, Trends, and Forecasts” announced by Global
Industry Analysts Inc., provides a
comprehensive review of market trends, growth drivers, product/service launches
and strategic industry activities of major companies worldwide. The report
provides market estimates and projections for major geographic markets
including the US and Rest of World. Product segments analyzed in the report
include Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial
Pancreas and Artificial Lungs. Additionally, the report analyzes Artificial
Kidneys/ Dialyzers by major geographic markets, including the US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa, and
Latin America; and Insulin Pumps (External) market by Geographic Region – US,
Europe and Rest of World.
Global Industry
Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.
For cutting edge analyst reviews on top industries
Follow us on Twitter;
Connect with us on LinkedIn
Comments
Post a Comment